{
    "clinical_study": {
        "@rank": "92561", 
        "arm_group": {
            "arm_group_label": "Embeda", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "Safety and pharmacokinetics of an abuse-deterrent, extended-release formulation of morphine\n      sulfate with a sequestered naltrexone core in children 7-17 with moderate-severe chronic\n      pain."
        }, 
        "brief_title": "Safety and Pharmacokinetic Study of EMBEDA in Children Ages 7-17 With Chronic Pain", 
        "completion_date": {
            "#text": "December 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Moderate-severe Chronic Pain (All Types)", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Children 7-17 with moderate to severe chronic pain requiring around the clock\n             treatment with an opioid analgesic for a period of 5 days prior to screening.\n\n        Exclusion Criteria:\n\n          -  Columbia-Suicide Severity Rating Scale (C-SSRS) for suicidal ideation and behavior in\n             past year.\n\n          -  Hypersensitivity to morphine, naltrexone"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "17 Years", 
            "minimum_age": "7 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 5, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02101554", 
            "org_study_id": "B4541006"
        }, 
        "intervention": [
            {
                "arm_group_label": "Embeda", 
                "description": "Oral/Capsule, once per day or twice per day dosing; Treatment duration consists of a 1- to 4-week Conversion/Titration Phase leading to a 6-week Maintenance Treatment duration.", 
                "intervention_name": "Ages 7-11", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Embeda", 
                "description": "Oral/Capsule, once per day or twice per day dosing; Treatment duration consists of a 1- to 4-week Conversion/Titration Phase leading to a 6-week Maintenance Treatment duration.", 
                "intervention_name": "ages 12-17", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Pediatric", 
            "chronic pain indication", 
            "controlled release morphine"
        ], 
        "lastchanged_date": "May 22, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B4541006&StudyName=Safety%20and%20Pharmacokinetic%20Study%20of%20EMBEDA%20in%20Children%20Ages%207-17%20with%20Chronic%20Pain"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open Label Study to Evaluate the Safety and Pharmacokinetics of PF-06412528 in Children 7-17 Years for the Treatment of Moderate to Severe Chronic Pain", 
        "overall_contact": {
            "last_name": "Pfizer CT.gov Call Center", 
            "phone": "1-800-718-1021"
        }, 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes.  Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling.  Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.", 
                "measure": "Apparent Oral Clearance (CL/F)", 
                "safety_issue": "No", 
                "time_frame": "4 weeks post-dose"
            }, 
            {
                "description": "Vd is the theoretical volume that the total amount of administered drug would have to occupy to provide the same concentration as it currently is in the blood plasma.", 
                "measure": "Volume of Distribution (Vd/F)", 
                "safety_issue": "No", 
                "time_frame": "4 weeks post-dose"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02101554"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Exposure levels of the metabolites of morphine and naltrexone in plasma samples", 
            "measure": "Pharmacokinetic evaluation", 
            "safety_issue": "No", 
            "time_frame": "4 weeks post-dose"
        }, 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}